May 1, 2022 2:00 pm EDT Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Apr 26, 2022 4:05 pm EDT RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Mar 23, 2022 7:00 am EDT Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Feb 22, 2022 7:00 am EST Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Feb 9, 2022 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Nov 12, 2021 4:05 pm EST Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Oct 13, 2021 8:10 am EDT Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
Oct 12, 2021 4:05 pm EDT Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
Sep 22, 2021 4:05 pm EDT Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
